Drug Profile
Sirolimus-eluting coronary stent - Carbostent and Implantable Devices
Alternative Names: Cre8; DES - Cre8™Latest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator Carbostent & Implantable Devices
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery disease
Most Recent Events
- 21 Sep 2017 Phase-III development is ongoing in China (NCT02360423)
- 01 Nov 2014 Phase-III clinical trials in Coronary artery disease in China (Intracoronary)
- 16 Jul 2011 Registered for Coronary artery disease in European Union (Intracoronary)